Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Wages, Salaries and Other
Ratios

Revolution Medicines (RVMD) Receivables - Net (2020 - 2023)

Revolution Medicines has reported Receivables - Net over the past 4 years, most recently at $1.3 million for Q4 2023.

  • Quarterly results put Receivables - Net at $1.3 million for Q4 2023, down 73.16% from a year ago — trailing twelve months through Dec 2023 was $1.3 million (down 73.16% YoY), and the annual figure for FY2023 was $1.3 million, down 73.16%.
  • Receivables - Net for Q4 2023 was $1.3 million at Revolution Medicines, up from $309000.0 in the prior quarter.
  • Over the last five years, Receivables - Net for RVMD hit a ceiling of $7.6 million in Q1 2021 and a floor of $309000.0 in Q3 2023.
  • Median Receivables - Net over the past 4 years was $5.4 million (2022), compared with a mean of $4.8 million.
  • Biggest five-year swings in Receivables - Net: dropped 7.26% in 2021 and later tumbled 93.74% in 2023.
  • Revolution Medicines' Receivables - Net stood at $6.4 million in 2020, then dropped by 7.26% to $5.9 million in 2021, then decreased by 21.18% to $4.7 million in 2022, then plummeted by 73.16% to $1.3 million in 2023.
  • The last three reported values for Receivables - Net were $1.3 million (Q4 2023), $309000.0 (Q3 2023), and $2.5 million (Q2 2023) per Business Quant data.